
Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP).

Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.
Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.
Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.

Dr. Victoria Werth explains how diagnosing BP can pose many difficulties in patients due to the variation of symptoms and symptom severity. Dr. Werth also discusses what burden and challenges BP patients might expect as a result.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.
Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.
This symposium explores the key role type 2 inflammation plays in atopic dermatitis and prurigo nodularis and debunks common misconceptions about these skin diseases with key insights from Drs Ahuva Cices and Naiem Issa.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?
Dr. Elena Netchiporouk discusses the chronic nature of CSU at EADV 2025.